These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

750 related items for PubMed ID: 33999797

  • 41. Comparison of in vitro synergistic effect between clarithromycin or azithromycin in combination with amikacin against Mycobacterium intracellulare.
    Zhang Z, Lu J, Du Y, Xie F, Wang Y, Sun B, Pang Y.
    J Glob Antimicrob Resist; 2019 Sep; 18():183-186. PubMed ID: 30953831
    [Abstract] [Full Text] [Related]

  • 42. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
    Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K, Caccitolo J, Alvarez J, Shepherd S, Wilson R, Graviss EA, Wallace RJ.
    Am J Respir Crit Care Med; 2006 Oct 15; 174(8):928-34. PubMed ID: 16858014
    [Abstract] [Full Text] [Related]

  • 43. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group.
    Shafran SD, Talbot JA, Chomyc S, Davison E, Singer J, Phillips P, Salit I, Walmsley SL, Fong IW, Gill MJ, Rachlis AR, Lalonde RG.
    Clin Infect Dis; 1998 Dec 15; 27(6):1401-5. PubMed ID: 9868650
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.
    Brown-Elliott BA, Iakhiaeva E, Griffith DE, Woods GL, Stout JE, Wolfe CR, Turenne CY, Wallace RJ.
    J Clin Microbiol; 2013 Oct 15; 51(10):3389-94. PubMed ID: 23946523
    [Abstract] [Full Text] [Related]

  • 48. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST.
    Hombach M, Somoskövi A, Hömke R, Ritter C, Böttger EC.
    Int J Med Microbiol; 2013 Jul 15; 303(5):270-6. PubMed ID: 23689069
    [Abstract] [Full Text] [Related]

  • 49. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease.
    Ye JJ, Wu TS, Chiang PC, Lee MH.
    J Microbiol Immunol Infect; 2007 Aug 15; 40(4):342-8. PubMed ID: 17712469
    [Abstract] [Full Text] [Related]

  • 50. Clinical features of non-tuberculous mycobacterial disease: comparisons between smear-positive and smear-negative cases, and between Mycobacterium avium and Mycobacterium intracellulare.
    Obayashi Y, Fujita J, Suemitsu I, Kamei T, Nii M, Takahara J.
    Int J Tuberc Lung Dis; 1998 Jul 15; 2(7):597-602. PubMed ID: 9661829
    [Abstract] [Full Text] [Related]

  • 51. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
    Koga T, Fukuoka T, Doi N, Harasaki T, Inoue H, Hotoda H, Kakuta M, Muramatsu Y, Yamamura N, Hoshi M, Hirota T.
    J Antimicrob Chemother; 2004 Oct 15; 54(4):755-60. PubMed ID: 15347635
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
    van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL.
    Am J Respir Crit Care Med; 2012 Sep 15; 186(6):559-65. PubMed ID: 22744719
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Antibacterial activity and clinical efficacy of sparfloxacin in Mycobacterium avium-intracellulare complex infection.
    Horiguchi T, Kondo R, Miyazaki J, Shiga M, Sugiyama M, Handa M, Munekata E.
    J Int Med Res; 2004 Sep 15; 32(5):530-9. PubMed ID: 15458286
    [Abstract] [Full Text] [Related]

  • 57. Genotyping and clarithromycin susceptibility testing of Mycobacterium avium subsp. hominissuis isolated in Tuscany, Italy.
    Genua F, Menichini M, Lari N, Rindi L.
    Infect Genet Evol; 2018 Nov 15; 65():144-149. PubMed ID: 30055327
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Identification and partial characterization of Mycobacterium avium and Mycobacterium intracellulare by using DNA probes.
    Saito H, Tomioka H, Sato K, Tasaka H, Tsukamura M, Kuze F, Asano K.
    J Clin Microbiol; 1989 May 15; 27(5):994-7. PubMed ID: 2745706
    [Abstract] [Full Text] [Related]

  • 60. Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.
    Shin SH, Jhun BW, Kim SY, Choe J, Jeon K, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ.
    Antimicrob Agents Chemother; 2018 Oct 15; 62(10):. PubMed ID: 30104265
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.